Scholarlink

<p>Interferon lambda (IFN-λ) is produced early by hematopoietic or epithelial cells and acts as a primary mediator of frontline antiviral defense without inducing inflammatory responses. However, whether hepatocytes, rather than immune cells, can secrete IFN-λs to protect against bacterial infection remains unestablished. Here, we demonstrate that hepatocytes secrete IFN-λs in response to bacterial stimulation both in vivo and in vitro, and that this secreted IFN-λs directly inhibits bacterial proliferation. Mechanistically, during in vitro bacterial infection, the upregulation and activation of the transcription factor IRF7 drive type III interferon (IFN-λ) production in hepatocytes through a cascading TLR4 signaling pathway, rather than via RIG-I or MDA5. Importantly, pretreatment with IFN-λs, through interaction with IFNLR1 in hepatocytes, increases the number of dead bacteria, improves systemic outcomes, and enhances survival in septic mice. Furthermore, sepsis patients show increased expression levels of IRF7, IFN-λ2, and IFN-λ3. These findings reveal that IFN-λs function as active mediators against bacterial infection, eliciting a unique antibacterial response to eliminate bacteria. This work further suggests that enhancing IFN-λs production in hepatocytes could serve as a potential therapeutic strategy for sepsis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Bacterial stimulation triggers IRF7-mediated IFN-λ production in hepatocytes to attenuate sepsis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月25日

查看全文
  • Wei Ma,
  • Junjie Shu,
  • Wanqi Tang,
  • Haoru Liu,
  • Hao Zhang,
  • Xue Yang,
  • Qiangguo Gao,
  • Huaping Liang,
  • Xia Yang

摘要

Interferon lambda (IFN-λ) is produced early by hematopoietic or epithelial cells and acts as a primary mediator of frontline antiviral defense without inducing inflammatory responses. However, whether hepatocytes, rather than immune cells, can secrete IFN-λs to protect against bacterial infection remains unestablished. Here, we demonstrate that hepatocytes secrete IFN-λs in response to bacterial stimulation both in vivo and in vitro, and that this secreted IFN-λs directly inhibits bacterial proliferation. Mechanistically, during in vitro bacterial infection, the upregulation and activation of the transcription factor IRF7 drive type III interferon (IFN-λ) production in hepatocytes through a cascading TLR4 signaling pathway, rather than via RIG-I or MDA5. Importantly, pretreatment with IFN-λs, through interaction with IFNLR1 in hepatocytes, increases the number of dead bacteria, improves systemic outcomes, and enhances survival in septic mice. Furthermore, sepsis patients show increased expression levels of IRF7, IFN-λ2, and IFN-λ3. These findings reveal that IFN-λs function as active mediators against bacterial infection, eliciting a unique antibacterial response to eliminate bacteria. This work further suggests that enhancing IFN-λs production in hepatocytes could serve as a potential therapeutic strategy for sepsis.